|Bid||0.0000 x 1200|
|Ask||0.0000 x 900|
|Day's Range||0.9200 - 1.0100|
|52 Week Range||0.6000 - 5.3600|
|Beta (3Y Monthly)||2.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2018 - Mar 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.33|
On a per-share basis, the Seattle-based company said it had profit of 1 cent. The biotechnology company posted revenue of $14.1 million in the period. For the year, the company reported that its loss narrowed ...
SEATTLE , March 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2018 . "The Company is focused ...
SEATTLE , March 12, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at Oppenheimer's 29 th Annual Healthcare Conference ...
The compensation hike comes at a time when CTI is cutting staff and subleasing extra office space in a bid to salvage its pipeline of cancer drug candidates.
SEATTLE , Feb. 20, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 8th Annual SVB Leerink Global Healthcare ...
The injection of funds comes at a critical time for CTI, which cut about half of its workforce in December as part of a restructuring plan.
SEATTLE , Feb. 11, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement ...
Dr. James Bianco has faced multiple debt collection and class action lawsuits since stepping down as CEO of CTI BioPharma in late 2016.
SEATTLE, Feb. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) today announced that the Company will withdraw its European Marketing Authorization Application (MAA) for pacritinib as a treatment for myelofibrosis. The decision follows recent interactions with the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), during which the Company learned that the committee was likely to formally adopt a negative opinion in its evaluation of the application. The Company is continuing to develop pacritinib for both U.S. and European registration as a treatment for myelofibrosis patients with severe thrombocytopenia. CTI plans to seek scientific guidance from the EMA before beginning the planned Phase 3 study, having already discussed the protocol design with the FDA last month. The Phase 3 trial is expected to begin enrollment in the third quarter of 2019.
The Company expects to report the determination of the optimal dose of pacritinib in mid-2019 following a meeting with the U.S. Food and Drug Administration (FDA). Topline efficacy and safety data are expected in the third quarter of 2019, with the new Phase 3 study targeted to commence enrollment in the third quarter of 2019.
SEATTLE, Dec. 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) announced today that it has received input from the U.S. Food and Drug Administration (FDA) at a recent Type C meeting on key elements of the design of a new randomized Phase 3 study of pacritinib in adult patients with myelofibrosis (primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis) and who have severe thrombocytopenia (as defined by patients with platelet counts of less than 50,000 per microliter), an indication that has been recognized by the medical community as an important unmet medical need.
It's one of two cancer drug startups that Dr. James Bianco has been linked to since leaving CTI BioPharma more than two years ago.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 13) Kezar Life Sciences Inc (NASDAQ: KZR ) Down In The Dumps ...
It’s CTI's latest attempt to salvage its pipeline of cancer drug candidates and reinvent the Seattle-based biotech after its co-founder and longtime CEO Dr. James Bianco stepped down in late 2016.
SEATTLE, Dec. 13, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) announced today a restructuring plan to improve efficiencies and reduce costs within the organization. As part of this plan, workforce reductions have been implemented that impact approximately 50 percent of the total number of the Company's employees. Cost savings of approximately $20 million primarily associated with reduced employee costs are expected over three years.
SEATTLE, Nov. 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) today announced that the Company has received a second round of questions related to the Day 180 List of Outstanding Issues, for the marketing authorization application (MAA) for pacritinib, from the European Medicines Agency (EMA). The Company plans to submit responses to the EMA, which will include data from the ongoing open label PAC203 trial, by the end of the year.
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -30.00% and 20.50%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Seattle-based company said it had a loss of 26 cents. The biotechnology company posted revenue of $723,000 in the period. The company's shares closed at $1.71. A year ago, they ...
-Management to Host Conference Call/Webcast Today at 4:30 p.m. Eastern Time- SEATTLE , Nov. 1, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the third quarter ...
SEATTLE , Oct. 25, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2018 financial results on Thursday, November ...
Investors need to pay close attention to CTI BioPharma (CTIC) stock based on the movements in the options market lately.
SEATTLE, Oct. 1, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) today announced that following a planned second interim data review of the PAC203 study by the Independent Data Monitoring Committee (IDMC), the study will continue to the full enrollment of 150 patients. The IDMC did not identify significant drug- or dose-related safety concerns and specifically did not identify any concerns around hemorrhagic or cardiac toxicity.
SEATTLE , Sept. 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare ...